Evidence map›Paper›PMID 36223968›Full record

ArticleBMJ open2022

Cohort profile: the Scottish Diabetes Research Network national diabetes cohort - a population-based cohort of people with diabetes in Scotland.

Stuart J McGurnaghan, Luke A K Blackbourn, Thomas M Caparrotta, Joseph Mellor, Anna Barnett, Andy Collier, Naveed Sattar, John McKnight, John Petrie, Sam Philip and 8 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Cohort Profile: The North East London Diabetes Study (NELDS).International journal of epidemiology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025 · on this map
    Observational
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 3 countries.

Stuart J McGurnaghanMRC Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK stuart.mcgurnaghan@ed.ac.uk.ORCID 0000-0002-3292-4633
Luke A K BlackbournMRC Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-4234-8040
Thomas M CaparrottaMRC Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-9009-9179
Joseph MellorMRC Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-1452-887X
Anna BarnettNinewells Hospital, The Scottish Diabetes Research Network, Dundee, UK.ORCID 0000-0002-6345-0194
Andy CollierSchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.ORCID 0000-0001-5220-6244
Naveed SattarInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-1604-2593
John McKnightEdinburgh Centre for Endocrinology, Western General Hospital, Edinburgh, UK.ORCID 0000-0002-8214-7625
John PetrieInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-4894-9819
Sam PhilipInstitute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.ORCID 0000-0001-6164-211X
Robert LindsayBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.ORCID 0000-0002-9868-5217
Katherine HughesInstitute of Health and Wellbeing, University of Glasgow, Glasgow, UK.ORCID 0000-0001-5278-5282
David McAllisterInstitute of Health and Wellbeing, University of Glasgow, Glasgow, UK.ORCID 0000-0003-3550-1764
Graham P LeeseDepartment of Medicine, Ninewells Hospital and Medical School, Dundee, UK.ORCID 0000-0003-0570-5678
Ewan R PearsonDivision of Molecular & Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK.ORCID 0000-0001-9237-8585
Sarah WildUsher Institute, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-7824-2569
Paul M McKeigueUsher Institute, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-5217-1034
Helen M ColhounMRC Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-8345-3288
University of Edinburgh · GBUniversity of Glasgow · GBNinewells Hospital · GBBritish Heart Foundation · GBGlasgow Caledonian University · GBNHS Fife · GBUniversity of Aberdeen · GBUniversity of Dundee · GBWestern General Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe Scottish Diabetes Research Network (SDRN)-diabetes research platform was established to combine disparate electronic health record data into research-ready linked datasets for diabetes research in Scotland. The resultant cohort, 'The SDRN-National Diabetes Dataset (SDRN-NDS)', has many uses, for example, understanding healthcare burden and socioeconomic trends in disease incidence and prevalence, observational pharmacoepidemiology studies and building prediction tools to support clinical decision making.

participantsWe estimate that >99% of those diagnosed with diabetes nationwide are captured into the research platform. Between 2006 and mid-2020, the cohort comprised 472 648 people alive with diabetes at any point in whom there were 4 million person-years of follow-up. Of the cohort, 88.1% had type 2 diabetes, 8.8% type 1 diabetes and 3.1% had other types (eg, secondary diabetes). Data are captured from all key clinical encounters for diabetes-related care, including diabetes clinic, primary care and podiatry and comprise clinical history and measurements with linkage to blood results, microbiology, prescribed and dispensed drug and devices, retinopathy screening, outpatient, day case and inpatient episodes, birth outcomes, cancer registry, renal registry and causes of death. FINDINGS TO DATE: There have been >50 publications using the SDRN-NDS. Examples of recent key findings include analysis of the incidence and relative risks for COVID-19 infection, drug safety of insulin glargine and SGLT2 inhibitors, life expectancy estimates, evaluation of the impact of flash monitors on glycaemic control and diabetic ketoacidosis and time trend analysis showing that diabetic ketoacidosis (DKA) remains a major cause of death under age 50 years. The findings have been used to guide national diabetes strategy and influence national and international guidelines. FUTURE PLANS: The comprehensive SDRN-NDS will continue to be used in future studies of diabetes epidemiology in the Scottish population. It will continue to be updated at least annually, with new data sources linked as they become available.

Indexed as

COVID-19Diabetes Mellitus, Type 2Diabetic KetoacidosisSodium-Glucose Transporter 2 InhibitorsHumansInsulin GlargineMiddle AgedScotlandInsulin GlargineSodium-Glucose Transporter 2 InhibitorsDIABETES & ENDOCRINOLOGYEPIDEMIOLOGYHealth informatics

Identifiers

PMID36223968
PMCPMC9562713
OpenAlexW4304695505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.